Articles

Find an Article

Filter articles

Applied Filters

Showing 31 to 40 of 256 results

Will the EPO’s Enlarged Board hear the Broad’s CRISPR case?

EPO13-07-2018Jakob Wested, Timo Minssen, Esther van Zimmeren

As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.

LSIPR 50 2018: At the head of an experiment in innovation

France09-07-2018

Marie-Paule Kieny of the Drugs for Neglected Diseases Initiative is on a mission to remind stakeholders and governments that there is a moral imperative to pursue the fight against neglected diseases, as she tells LSIPR.

LSIPR 50 2018: A decade in the making, a Parkinson’s breakthrough

UK06-07-2018

A team at the University of Dundee has announced a major breakthrough in the understanding of Parkinson’s disease. LSIPR heard more from Miratul Muqit and Daan van Aalten of the university’s school of life sciences.

LSIPR 50 2018: Uniting the IP chorus

UK02-07-2018

Brexit has created many uncertainties in the IP arena and the CEO of the UK Intellectual Property Office is urging stakeholders to speak up, so that the office isn’t the “lone voice” advocating the importance of IP.

The future of precision medicine part 1: challenges and opportunities

UK, US13-06-2018Daniel Lim

The healthcare industry and governments around the world are turning to precision medicine as an opportunity and a potential saviour. Daniel Lim of Kirkland & Ellis discusses the issues around translating the promise of precision medicine into real world clinical practice.

Conference preview: International Pharma Patent Term Extensions Forum

Germany04-06-2018

C5’s International Pharma Patent Term Extensions Forum, which will be held in Munich, Germany on June 19 and 20, will provide guidance on patent term extensions in the world’s key IP regions, as LSIPR finds out.

Medicines regulation after Brexit: compromise the key

EU04-06-2018

With Brexit looming, questions are being asked about the future regulatory relationship between the EU and the UK, with life sciences companies wondering how they will be affected. LSIPR reports.

Regulation and licensing: the CRISPR conundrum continues

China, EU, US04-06-2018

As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

Testing the waters

EU02-06-2018Anthony Carlick

The UK Intellectual Property Office’s official opinion service on infringement and validity can be a useful tool for parties seeking to file oppositions at the European Patent Office, as Anthony Carlick of Dennemeyer & Associates reports.

Clearing a way through the CRISPR patent jungle

Belgium, Denmark, International08-05-2018Timo Minssen, Esther van Zimmeren, Jakob Wested

There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested.

Showing 31 to 40 of 256 results

LSIPR